Search

Your search keyword '"Miguel, Alcoceba"' showing total 14 results
Start Over Author "Miguel, Alcoceba" Journal hematological oncology
14 results on '"Miguel, Alcoceba"'

1. TESTICULAR DIFFUSE LARGE B‐CELL LYMPHOMA: CLINICO‐BIOLOGICAL CHARACTERIZATION, EVALUATION OF TREATMENT RESPONSE AND SURVIVAL

Author

J. Bosch, Pablo Mozas, T. Gustavo, Neus Villamor, G. Frigola, N. Kelleher, Ferran Nadeu, Silvia Martín, Laura Magnano, Alfredo Rivas-Delgado, Armando López-Guillermo, Tycho Baumann, Olga Balagué, Sílvia Beà, M. Grau, A. Muntañola, C. Barcena, A. Martín García-Sancho, Miguel Alcoceba, E. Campo, Cristina López, Fina Climent, Juan-Manuel Sancho, Eva González-Barca, Eva Giné, L. Luizaga, and Andrea Rivero

Subjects
Cancer Research, Treatment response, Pathology, medicine.medical_specialty, Oncology, business.industry, medicine, Hematology, General Medicine, medicine.disease, business, Diffuse large B-cell lymphoma
Published
2021
Full Text
View/download PDF

2. OUTCOME OF 133 PATIENTS WITH FOLLICULAR LYMPHOMA (FL) PROGRESSING BEFORE 24 MONTHS (POD24) AFTER IMMUNOCHEMOTHERAPY: A GELTAMO STUDY

Author

S. Bobillo, L. Luizaga, Andrea Rivero, Miguel Alcoceba, Pablo Mozas, Laura Magnano, Eva Giné, Dolores Caballero, M. Huguet, Alfredo Rivas-Delgado, Sara Alonso-Álvarez, Santiago Mercadal, Mariana Bastos-Oreiro, Ana Jiménez-Ubieto, Juan-Manuel Sancho, A. Muntañola, Jordina Rovira, and Armando López-Guillermo

Subjects
Oncology, Cancer Research, medicine.medical_specialty, business.industry, Internal medicine, Follicular lymphoma, medicine, Hematology, General Medicine, medicine.disease, business, Outcome (game theory)
Published
2021
Full Text
View/download PDF

3. Exportin‐1 <scp>E571K</scp> mutation is a common finding in patients with classical <scp>Hodgkin</scp> lymphoma

Author

Marcos González, Oscar Blanco, Miguel Alcoceba, Isabel Prieto, Alejandro Medina, Luis G Díaz, Cristina Jimenez, María Eugenia Sarasquete, María C. Chillón, Almudena Navarro-Bailón, María Teresa García-Álvarez, Maria Dolores Caballero, Verónica González-Calle, Sara Alonso-Álvarez, and Ramón García-Sanz

Subjects
Cancer Research, Oncology, business.industry, Exportin-1, Mutation (genetic algorithm), Classical Hodgkin lymphoma, Cancer research, Medicine, In patient, Hematology, General Medicine, business
Published
2019
Full Text
View/download PDF

4. EVALUATION OF BONE MARROW INFILTRATION BY MULTIDIMENSIONAL FLOW CYTOMETRY IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA: SUB-STUDY OF A PHASE 2 GELTAMO CLINICAL TRIAL

Author

Francisco-Javier Peñalver, M. Guinea, B. Vidriales, Jesús María Hernández-Rivas, C. Grande, Alejandro Martín, R. Fernández, A. Batlle, María Teresa García-Álvarez, Juan-Manuel Sancho, MJ Peñarrubia, A. Orfao, J.J. Pérez, Susana Barrena, Miguel Alcoceba, and Mónica Baile

Subjects
Cancer Research, Pathology, medicine.medical_specialty, Bone marrow infiltration, medicine.diagnostic_test, business.industry, Hematology, General Medicine, medicine.disease, Flow cytometry, Clinical trial, Oncology, Phase (matter), medicine, In patient, business, Diffuse large B-cell lymphoma
Published
2019
Full Text
View/download PDF

5. Refractoriness to immunochemotherapy in follicular lymphoma: Predictive factors and outcome

Author

Eva González-Barca, Ruben Fernández-Álvarez, Helena Pomares, Alejandro Martín, Cristina Motlló, Miriam Moreno, Santiago Mercadal, Esther González-García, Miguel Alcoceba, Anna Sureda, Dolores Caballero, Juan-Manuel Sancho, Sara Alonso, Olga García, Josep-Maria Ribera, and Marc Sorigue

Subjects
Adult, Male, Cancer Research, medicine.medical_specialty, Multivariate analysis, Refractory period, Drug Resistance, Follicular lymphoma, survival, Gastroenterology, Young Adult, 03 medical and health sciences, 0302 clinical medicine, International Prognostic Index, follicular lymphoma, Refractory, Risk Factors, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, parasitic diseases, Humans, Medicine, Cumulative incidence, Lymphoma, Follicular, Aged, Aged, 80 and over, refractoriness, business.industry, transformation, Incidence (epidemiology), Hematology, General Medicine, Middle Aged, medicine.disease, immunochemotherapy, Treatment Outcome, Oncology, B symptoms, 030220 oncology & carcinogenesis, Immunology, Female, Immunotherapy, prognosis, medicine.symptom, business, 030215 immunology
Abstract

Follicular lymphoma is characterized by a good response to immunochemotherapy (ICT). However, a small percentage of patients responds poorly to treatment and seems to have a worse outcome. This study attempted to identify the predictive factors and outcome of refractoriness to first-line ICT. All patients diagnosed with stage II to IV follicular lymphoma between 2002 and 2014 and treated with first-line ICT in 4 Spanish institutions were analyzed. Those with no response or progression or relapse within 6 months of first-line response assessment were considered ICT refractory. Three hundred forty-three patients were included (median age 58 years, 48% male), of whom 53 (15%) were ICT refractory. On multivariate analysis, high-risk follicular lymphoma international prognostic index (FLIPI) score. B symptoms, and elevated beta 2-microglobulin were correlated with refractoriness, and refractoriness, high-risk FLIPI score, and beta 2-micro-globulin were correlated with overall survival (OS). Compared with ICT-sensitive, ICT-refractory patients had a higher incidence of histological transformation (5-year cumulative incidence 25% [14%-39%] vs. 6% [3%-10%], P < .001). a higher rate of refractoriness to second-line therapy (16/33 [48%] vs. 13/57 [23%], P = .01), and a lower 05 (5-year OS probability 38% [95% CI 23%-53%] vs. 87% [82%-92%%], P < .001). In conclusion, refractoriness to ICT was seen in 15% of patients and was predicted by high-FLIPI scores, B symptoms, and elevated serum beta 2-micrglobulin. Immunochemotherapy-refractory patients had a worse prognosis than ICT-sensitive patients, and current treatment options for this subgroup are not satisfactory.

Published
2017
Full Text
View/download PDF

6. Prediction of peripheral neuropathy in multiple myeloma patients receiving bortezomib and thalidomide: a genetic study based on a single nucleotide polymorphism array

Author

Isabel Prieto, Marcos González Díaz, María Jesús Blanchard, Joaquin Martinez-Lopez, Maria-Victoria Mateos, Luis A. Corchete, Albert Oriol, Rafael Martínez, Jesús F. San Miguel, María García-Álvarez, Santiago Barrio, Juan José Lahuerta, María C. Chillón, Javier de la Rubia, Cristina Jimenez, Ramón García-Sanz, María Eugenia Sarasquete, Immaculada Rapado, Miguel Alcoceba, and Noemi Puig

Subjects
0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, business.industry, Bortezomib, Genome-wide association study, Single-nucleotide polymorphism, Hematology, General Medicine, medicine.disease, Thalidomide, 03 medical and health sciences, 030104 developmental biology, Peripheral neuropathy, Internal medicine, medicine, Adverse effect, business, Exome, Multiple myeloma, medicine.drug
Abstract

Bortezomib- and thalidomide-based therapies have significantly contributed to improved survival of multiple myeloma (MM) patients. However, treatment-induced peripheral neuropathy (TiPN) is a common adverse event associated with them. Risk factors for TiPN in MM patients include advanced age, prior neuropathy, and other drugs, but there are conflicting results about the role of genetics in predicting the risk of TiPN. Thus, we carried out a genome-wide association study based on more than 300 000 exome single nucleotide polymorphisms in 172 MM patients receiving therapy involving bortezomib and thalidomide. We compared patients developing and not developing TiPN under similar treatment conditions (GEM05MAS65, NCT00443235). The highest-ranking single nucleotide polymorphism was rs45443101, located in the PLCG2 gene, but no significant differences were found after multiple comparison correction (adjusted P = .1708). Prediction analyses, cytoband enrichment, and pathway analyses were also performed, but none yielded any significant findings. A copy number approach was also explored, but this gave no significant results either. In summary, our study did not find a consistent genetic component associated with TiPN under bortezomib and thalidomide therapies that could be used for prediction, which makes clinical judgment essential in the practical management of MM treatment.

Published
2016
Full Text
View/download PDF

7. Prediction of peripheral neuropathy in multiple myeloma patients receiving bortezomib and thalidomide: a genetic study based on a single nucleotide polymorphism array

Author

Ramón, García-Sanz, Luis Antonio, Corchete, Miguel, Alcoceba, María Carmen, Chillon, Cristina, Jiménez, Isabel, Prieto, María, García-Álvarez, Noemi, Puig, Immaculada, Rapado, Santiago, Barrio, Albert, Oriol, María Jesús, Blanchard, Javier, de la Rubia, Rafael, Martínez, Juan José, Lahuerta, Marcos, González Díaz, María Victoria, Mateos, Jesús Fernando, San Miguel, Joaquín, Martínez-López, and María Eugenia, Sarasquete

Subjects
Bortezomib, Male, Genotype, Humans, Peripheral Nervous System Diseases, Female, Multiple Myeloma, Polymorphism, Single Nucleotide, Thalidomide
Abstract

Bortezomib- and thalidomide-based therapies have significantly contributed to improved survival of multiple myeloma (MM) patients. However, treatment-induced peripheral neuropathy (TiPN) is a common adverse event associated with them. Risk factors for TiPN in MM patients include advanced age, prior neuropathy, and other drugs, but there are conflicting results about the role of genetics in predicting the risk of TiPN. Thus, we carried out a genome-wide association study based on more than 300 000 exome single nucleotide polymorphisms in 172 MM patients receiving therapy involving bortezomib and thalidomide. We compared patients developing and not developing TiPN under similar treatment conditions (GEM05MAS65, NCT00443235). The highest-ranking single nucleotide polymorphism was rs45443101, located in the PLCG2 gene, but no significant differences were found after multiple comparison correction (adjusted P = .1708). Prediction analyses, cytoband enrichment, and pathway analyses were also performed, but none yielded any significant findings. A copy number approach was also explored, but this gave no significant results either. In summary, our study did not find a consistent genetic component associated with TiPN under bortezomib and thalidomide therapies that could be used for prediction, which makes clinical judgment essential in the practical management of MM treatment.

Published
2016

8. Whole-exome analysis of abnormalities leading to Waldenström's macroglobulinemia transformation into aggressive lymphoma

Author

Luis Marín, María Isabel Prieto-Conde, M. González, María Teresa García-Álvarez, Ramón García-Sanz, G.R. Ordóñez, Rocío Corral, Sara Alonso-Álvarez, Miguel Alcoceba, Noemi Puig, Norma C. Gutiérrez, Ana Balanzategui, Cristina Jimenez, María Eugenia Sarasquete, and María C. Chillón

Subjects
Cancer Research, Transformation (genetics), Oncology, business.industry, Cancer research, Macroglobulinemia, Medicine, Aggressive lymphoma, Hematology, General Medicine, business, Exome
Published
2017
Full Text
View/download PDF

9. PATIENTS WITH FOLLICULAR LYMPHOMA (FL) IN MAINTAINED COMPLETE RESPONSE (CR) AT 30 MONTHS SHOW A SURVIVAL SIMILAR TO A SEX- AND AGE-MATCHED SPANISH GENERAL POPULATION

Author

M. González, Ana Jiménez-Ubieto, Sara Alonso-Álvarez, M. J. Terol, Marcio Andrade-Campos, M. Canals, E. de Cabo, Miguel Alcoceba, Alejandro Martín, Juan-Manuel Sancho, Armando López-Guillermo, Emilia Pardal, Santiago Mercadal, Maria Dolores Caballero, Jose Luis Bello, Silvana Novelli, Antonio Salar, S. González de Villambrosía, Reyes Arranz, A. Muntañola, María Infante, Guillermo Rodríguez, Lourdes Lopez, Laura Magnano, and Alfredo Rivas-Delgado

Subjects
Cancer Research, education.field_of_study, business.industry, Population, Follicular lymphoma, Physiology, Hematology, General Medicine, medicine.disease, 03 medical and health sciences, 0302 clinical medicine, Oncology, 030220 oncology & carcinogenesis, Immunology, medicine, business, education, Complete response, 030215 immunology
Published
2017
Full Text
View/download PDF

10. GENE MUTATIONS AND COPY NUMBER ALTERATIONS (CNA) PREDICT FOR EARLY FAILURE IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) TREATED WITH R-CHOP

Author

Santiago Mercadal, Kennosuke Karube, Jordina Rovira, Itziar Salaverria, Ivan Dlouhy, Ferran Nadeu, Javier Briones, Juan-Manuel Sancho, Patricia Pérez-Galán, Guillem Clot, Alfredo Rivas-Delgado, L. Escola, Alexandra Valera, Pedro Jares, Miguel Alcoceba, David Martín-García, Luis Colomo, Armando López-Guillermo, Anna Enjuanes, Ana Mozos, Antonio Salar, E. Campo, and Blanca Gonzalez

Subjects
Cancer Research, Pathology, medicine.medical_specialty, business.industry, Hematology, General Medicine, Gene mutation, medicine.disease, Oncology, Medicine, In patient, business, Early failure, Diffuse large B-cell lymphoma
Published
2017
Full Text
View/download PDF

11. APPLICATION OF CELL-OF-ORIGIN SUBTYPES DETERMINED BY DIGITAL GENE EXPRESSION IN HIV-RELATED DIFFUSE LARGE B-CELL LYMPHOMAS

Author

Pilar Miralles, Maria Joao Baptista, Silvia Montoto, Eugenia Abella, Josep-Maria Ribera, Eva González-Barca, Gustavo Tapia, C. García-Ballesteros, José M. Moraleda, Ferran Vall-Llovera, Armando López-Guillermo, José-Luis Mate, John G. Gribben, Blanca Gonzalez-Farre, Juan-Manuel Sancho, M. J. Terol, Josep Muncunill, Mariarita Calaminici, Ana-Maria Muñoz-Marmol, Mariano Provencio, Miguel Alcoceba, Pau Abrisqueta, José-Tomás Navarro, A. Martinez, and Javier Briones

Subjects
Cancer Research, medicine.anatomical_structure, Oncology, Cell of origin, Gene expression, Human immunodeficiency virus (HIV), medicine, Hematology, General Medicine, Biology, medicine.disease_cause, Molecular biology, B cell
Published
2017
Full Text
View/download PDF

12. Post-transplant monomorphic Burkitt's lymphoma: Clinical characteristics and outcome of a multicenter series

Author

S. González de Villambrosía, A. López, Juan-Manuel Sancho, Josep Castellví, Blanca Sanchez-Gonzalez, Eva Giné, Miguel Alcoceba, Pau Abrisqueta, Eva González-Barca, Samuel Romero, Francesc Bosch, and Sabela Bobillo

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Series (stratigraphy), business.industry, Hematology, General Medicine, medicine.disease, Outcome (game theory), Post transplant, Internal medicine, medicine, business, Burkitt's lymphoma
Published
2017
Full Text
View/download PDF

13. THE RISK OF TRANSFORMATION OF FOLLICULAR LYMPHOMA 'TRANSFORMED' BY RITUXIMAB: THE ARISTOTLE STUDY PROMOTED BY THE EUROPEAN LYMPHOMA INSTITUTE

Author

Vittoria Tarantino, Guillaume Cartron, Clémentine Sarkozy, Miguel Alcoceba, Carla Minoia, Sara Alonso, Luana Conte, Massimo Federico, C. Rusconi, Marielle J. Wondergem, F. Morschhauser, Eva Kimby, A. Lopez Guillermo, Martine E.D. Chamuleau, Gilles Salles, Emanuele Zucca, Silvia Montoto, Bertrand Coiffier, Luigi Marcheselli, Dolores Caballero, Igor Aurer, E. Paszkiewicz-Kozik, Sandra Lockmer, Djamila E. Issa, and M. G. Da Silva

Subjects
Cancer Research, business.industry, Follicular lymphoma, Hematology, General Medicine, medicine.disease, Lymphoma, 03 medical and health sciences, Transformation (genetics), 0302 clinical medicine, Oncology, 030220 oncology & carcinogenesis, Immunology, medicine, Cancer research, Rituximab, business, 030215 immunology, medicine.drug
Published
2017
Full Text
View/download PDF

14. CLINICAL CHARACTERISTICS AND PROGNOSIS OF ELDERLY (>70 YEARS) FOLLICULAR LYMPHOMA IN THE RITUXIMAB ERA: MULTICENTRE RETROSPECTIVE ANALYSIS OF THE GELTAMO SPANISH GROUP

Author

Antonia Rodriguez, Laura Magnano, S. González de Villambrosía, Silvia Monsalvo, A. Muntañola, Maria Stefania Infante, Santiago Mercadal, Guillermo Rodríguez, Ana-Isabel Teruel, Sara Alonso-Álvarez, Miriam Moreno, Armando López-Guillermo, Jimena Cannata, M. González, Natalia Espinosa-Lara, Silvana Novelli, L.I. López, Marcio Andrade-Campos, Jose Luis Bello, Alejandro Martín, Francesc Garcia-Pallarols, Miguel Alcoceba, Emilia Pardal, E. de Cabo, Juan-Manuel Sancho, and Maria Dolores Caballero

Subjects
Cancer Research, Pediatrics, medicine.medical_specialty, business.industry, Follicular lymphoma, Hematology, General Medicine, medicine.disease, Oncology, Retrospective analysis, Medicine, Rituximab, business, medicine.drug
Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results